In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until condition progression or perhaps the members are not able to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells for each replicate were being https://how-does-abbv-744-work-in57902.wizzardsblog.com/31914396/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options